259 related articles for article (PubMed ID: 30753459)
1. Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
Farmer RE; Ford D; Mathur R; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
Int J Epidemiol; 2019 Apr; 48(2):527-537. PubMed ID: 30753459
[TBL] [Abstract][Full Text] [Related]
2. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Currie CJ; Poole CD; Gale EA
Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
[TBL] [Abstract][Full Text] [Related]
3. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study.
Elder DH; Singh JS; Levin D; Donnelly LA; Choy AM; George J; Struthers AD; Doney AS; Lang CC
Eur J Heart Fail; 2016 Jan; 18(1):94-102. PubMed ID: 26663216
[TBL] [Abstract][Full Text] [Related]
4. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records.
Doran W; Tunnicliffe L; Muzambi R; Rentsch CT; Bhaskaran K; Smeeth L; Brayne C; Williams DM; Chaturvedi N; Eastwood SV; Dunachie SJ; Mathur R; Warren-Gash C
BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38272537
[TBL] [Abstract][Full Text] [Related]
5. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
6. Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes.
Rodgers LR; Weedon MN; Henley WE; Hattersley AT; Shields BM
BMJ Open; 2017 Oct; 7(10):e017989. PubMed ID: 29025846
[TBL] [Abstract][Full Text] [Related]
7. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
[TBL] [Abstract][Full Text] [Related]
8. Metformin use and survival after colorectal cancer: A population-based cohort study.
Mc Menamin ÚC; Murray LJ; Hughes CM; Cardwell CR
Int J Cancer; 2016 Jan; 138(2):369-79. PubMed ID: 26331456
[TBL] [Abstract][Full Text] [Related]
9. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Kowall B; Stang A; Rathmann W; Kostev K
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
[TBL] [Abstract][Full Text] [Related]
10. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
11. Metformin Treatment Among Men With Diabetes and the Risk of Prostate Cancer: A Population-Based Historical Cohort Study.
Freedman LS; Agay N; Farmer R; Murad H; Olmer L; Dankner R
Am J Epidemiol; 2022 Mar; 191(4):626-635. PubMed ID: 34893792
[TBL] [Abstract][Full Text] [Related]
12. Metformin Treatment and Cancer Risk: Cox Regression Analysis, With Time-Dependent Covariates, of 320,000 Persons With Incident Diabetes Mellitus.
Dankner R; Agay N; Olmer L; Murad H; Keinan Boker L; Balicer RD; Freedman LS
Am J Epidemiol; 2019 Oct; 188(10):1794-1800. PubMed ID: 31269196
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Metformin Strategies for Cancer Prevention: A Target Trial Emulation Using Electronic Health Records.
Dickerman BA; García-Albéniz X; Logan RW; Denaxas S; Hernán MA
Epidemiology; 2023 Sep; 34(5):690-699. PubMed ID: 37227368
[TBL] [Abstract][Full Text] [Related]
14. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
15. Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database.
Watson L; Das R; Farquhar R; Langerman H; Barnett AH
Curr Med Res Opin; 2016 Sep; 32(9):1465-75. PubMed ID: 26907851
[TBL] [Abstract][Full Text] [Related]
16. Metformin and the incidence of viral associated cancers in patients with type 2 diabetes.
Hicks BM; Yin H; Sinyavskaya L; Suissa S; Azoulay L; Brassard P
Int J Cancer; 2017 Jul; 141(1):121-128. PubMed ID: 28393359
[TBL] [Abstract][Full Text] [Related]
17. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
18. New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer.
Lu Y; García Rodríguez LA; Malgerud L; González-Pérez A; Martín-Pérez M; Lagergren J; Bexelius TS
Br J Cancer; 2015 Dec; 113(11):1607-14. PubMed ID: 26575601
[TBL] [Abstract][Full Text] [Related]
19. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study.
Bruderer SG; Bodmer M; Jick SS; Meier CR
Ann Rheum Dis; 2015 Sep; 74(9):1651-8. PubMed ID: 24728333
[TBL] [Abstract][Full Text] [Related]
20. Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Zhao H; Liu Z; Zhuo L; Shen P; Lin H; Sun Y; Zhan S
Front Endocrinol (Lausanne); 2022; 13():874344. PubMed ID: 35846337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
